TheraRadar
Clinical-Stage Companies / HAL Allergy

HAL Allergy

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 9/9/2024

14
Total Trials
2
Phase 3
7
Phase 2
1
Recruiting
98
Score

Pipeline by Phase

Phase 3
2
Phase 2
7
Phase 1
4

Therapeutic Focus

Allergic Rhinitis Allergic Rhinoconjunctivitis House Dust Mite Allergy Peanut Allergy House Dust Mite Rhinitis

Clinical Trials (14)

NCT06920771 Phase 3 ACTIVE NOT RECRUITING

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

Started: 9/9/2024

NCT02231307 Phase 3 COMPLETED

SUBLIVAC FIX Birch Phase III Short-term Efficacy

Started: 9/1/2014

NCT02556801 Phase 2 COMPLETED

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Started: 9/1/2015

NCT01438463 Phase 2 COMPLETED

PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis

Started: 9/1/2011

NCT01682070 Phase 2 COMPLETED

SUBLIVAC FIX Phleum Pratense DT/DRF

Started: 9/1/2012

NCT01639768 Phase 2 COMPLETED

SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

Started: 7/1/2012

NCT00932607 Phase 2 COMPLETED

SUBLIVAC® Birch PROBE Study

Started: 7/1/2009

NCT00973453 Phase 2 COMPLETED

Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

Started: 8/1/2009

NCT02991885 Phase 1 COMPLETED

HAL-MPE1 Safety and Tolerability Study

Started: 12/1/2016

NCT03758456 Phase 1 COMPLETED

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Started: 11/21/2018

NCT02345278 Phase 1 COMPLETED

SUBLIVAC FIX Mite Mixture Dose Tolerability Study

Started: 5/1/2015

NCT02163018 Phase 1 COMPLETED

HAL-MPE1 First-in-human

Started: 6/1/2014

NCT01918956 Phase 4 COMPLETED

PURETHAL Birch RUSH Study

Started: 9/1/2013

NCT01059266 Phase 4 COMPLETED

PURETHAL Grasses Rush Study

Started: 2/1/2010

Drug Candidates

PURETHAL Mites 50,000 AUeq/ml Biological/Vaccine: Placebo HAL-MPE1 HAL-MPE1 placebo SUBLIVAC FIX Phleum Prat. HAL-MRE1 SUBLIVAC FIX Birch SUBLIVAC FIX Mite mixture Placebo PURETHAL Birch, 20.000 AUM/ml
Activity Status: Slowing
Last Trial Started: 9/9/2024
Last Trial Ended: 9/1/2019
Trials (12 months): 0
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.